Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Safety Study of LY3372689 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3372689

First Posted Date: 2019-09-26

Last Posted Date: 2020-04-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 54

Registration Number: NCT04106206

Locations: 🇺🇸
Covance, Dallas, Texas, United States

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: LY3295668 Erbumine
Drug: Topotecan
Drug: Cyclophosphamide

First Posted Date: 2019-09-26

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 71

Registration Number: NCT04106219

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇧🇪
UZ Gent, Gent, Oost-Vlaanderen, Belgium
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

and more 14 locations

A Study of LY3435151 in Participants With Solid Tumors

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma
Gastric Adenocarcinoma
Cervical Carcinoma
Solid Tumor
Triple-negative Breast Cancer
Head and Neck Squamous Cell Carcinoma
Undifferentiated Pleomorphic Sarcoma
Leiomyosarcoma
High Grade Serous Ovarian Carcinoma

Interventions: Drug: LY3435151
Drug: Pembrolizumab

First Posted Date: 2019-09-23

Last Posted Date: 2021-08-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2

Registration Number: NCT04099277

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇯🇵
National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Tirzepatide
Drug: Insulin Glargine

First Posted Date: 2019-09-18

Last Posted Date: 2023-01-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 917

Registration Number: NCT04093752

Locations: 🇨🇳
Huizhou Municipal Central Hospital, Huizhou, Guangdong, China
🇨🇳
Hebei Medical University, Hengshui Shi, Hebei, China
🇦🇺
Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia

and more 64 locations

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Phase 3

Active, not recruiting

Conditions: Uveitis

Interventions: Drug: Baricitinib
Drug: Adalimumab

First Posted Date: 2019-09-12

Last Posted Date: 2024-12-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT04088409

Locations: 🇫🇷
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France
🇫🇷
Hôpital Universitaire Necker Enfants Malades, Paris, France
🇫🇷
Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France

and more 17 locations

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Phase 3

Recruiting

Conditions: Systemic Juvenile Idiopathic Arthritis

Interventions: Drug: Baricitinib
Drug: Tocilizumab

First Posted Date: 2019-09-12

Last Posted Date: 2024-12-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 58

Registration Number: NCT04088396

Locations: 🇧🇷
Hospital de Clínicas Da Universidade Estadual de Campinas, Campinas, São Paulo, Brazil
🇫🇷
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois, Vandoeuvre lès Nancy, Meurthe-et-Moselle, France
🇯🇵
Institute of Science Tokyo Hospital, Bunkyō, Tokyo, Japan

and more 64 locations

A Study of Baricitinib in Participants With Rheumatoid Arthritis

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Baricitinib
Drug: TNF Inhibitor

First Posted Date: 2019-09-12

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1300

Registration Number: NCT04086745

Locations: 🇺🇸
Arizona Research Clinic PLLC, Chandler, Arizona, United States
🇺🇸
Smart Cures Clinical Research, Anaheim, California, United States
🇺🇸
Wallace Rheumatic Study Center, Beverly Hills, California, United States

and more 116 locations

A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Galcanezumab

First Posted Date: 2019-09-11

Last Posted Date: 2021-06-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT04085289

Locations: 🇨🇳
HuaShan Hospital Affiliated To Fudan University, Shanghai, Shanghai, China

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2019-09-09

Last Posted Date: 2024-02-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 55

Registration Number: NCT04081337

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

A Study of Lasmiditan in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Lasmiditan

First Posted Date: 2019-09-09

Last Posted Date: 2021-07-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT04081324

Locations: 🇨🇳
HuaShan Hospital Affiliated To Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy